UPDATE: FX-111 Entered Clinical Trials Phase

The first-in-human Phase 1 trial is designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and early signs of anti-tumor activity for FX-111 just started recruiting.

FX-111 is a selective degrader of ARon, the transcriptionally active, hormone-bound form of the androgen receptor. That distinction matters because many current androgen-directed therapies mainly suppress signaling linked to the inactive receptor state, while FX-111 is designed to remove the active form itself.

The trial is being conducted in adult men with mCRPC (and other solid tumors) who have already progressed on androgen deprivation therapy and at least one prior potent androgen receptor pathway inhibitor such as abiraterone, enzalutamide, apalutamide, or darolutamide. In other words, this is an early study in a heavily pretreated population rather than a frontline trial.

Theoretically, FX-111 raises an interesting question: could an ARon-targeting degrader work even without ongoing androgen deprivation? Preclinical and company-derived descriptions suggest that targeting ARon may have broader potential across prostate cancer and may address disease driven by androgen receptor signaling even when circulating androgen levels are not fully suppressed.

That said, the current clinical trial does not test FX-111 without ADT. The eligibility criteria explicitly require progression on ADT, and the protocol remains in a castration-resistant setting where standard background androgen suppression is still part of the clinical framework. So while the mechanism makes the “no ADT” concept biologically plausible in theory, it is not yet supported by clinical evidence.

Clinical trial.